This article was downloaded by:

On: 26 January 2011

Access details: Access Details: Free Access

Publisher Taylor & Francis

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-

41 Mortimer Street, London W1T 3JH, UK



Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information: http://www.informaworld.com/smpp/title~content=t713597286

SYNTHESIS AND ANTIVIRAL EVALUATION OF N-GLYCOSIDES DERIVED FROM 6-AMINO-3-ARYL-2-METHYL-4-(3H)-QUINAZOLINONES

Mohamed A. Saleh^a; Youssef A. Abbas^b; Fouad Eabdel-Hai^a; Shaban A. Youssef^b
^a Chemistry Department, Faculty of Science, Tanta University, Egypt ^b Chemistry Department, Faculty of Education, Kafr El-Sheikh, Tanta University, Egypt

Online publication date: 31 December 2001

To cite this Article Saleh, Mohamed A., Abbas, Youssef A., Eabdel-Hai, Fouad and Youssef, Shaban A.(2001) 'SYNTHESIS AND ANTIVIRAL EVALUATION OF N-GLYCOSIDES DERIVED FROM 6-AMINO-3-ARYL-2-METHYL-4-(3H)-QUINAZOLINONES', Nucleosides, Nucleotides and Nucleic Acids, 20: 10, 1891 — 1902

To link to this Article: DOI: 10.1081/NCN-100107200 URL: http://dx.doi.org/10.1081/NCN-100107200

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: http://www.informaworld.com/terms-and-conditions-of-access.pdf

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

SYNTHESIS AND ANTIVIRAL EVALUATION OF N-GLYCOSIDES DERIVED FROM 6-AMINO-3-ARYL-2-METHYL-4-(3H)-QUINAZOLINONES

Mohamed A. Saleh, 1,* Youssef A. Abbas, Fouad Eabdel-Hai, and Shaban A. Youssef 2

¹Chemistry Department, Faculty of Science, Tanta University, Egypt ²Chemistry Department, Faculty of Education, Kafr El-Sheikh, Tanta University, Egypt

ABSTRACT

Reaction of monosaccharides (D-glucose, D-galactose, D-xylose or L-arabinose) with 6-amino-3-aryl-2-methyl-4-(3H) quinazolinones (1a-c) in boiling methanol yielded the corresponding N-glycopyranosides 3a-c, 4a-c, 5a,b and 6a,b. The N-glycopyranosides 3a-c, 4a-c, 5a,b and 6a,b were acetylated with acetic anhydride and pyridine to give the corresponding acetate derivatives 7a-c, 8a-c, 9a,b and 10a,b. The structures of all these glycosides were assessed by elemental analysis, IR, NMR and mass spectra. Some of these products were tested for anticancer and anti-AIDS activity.

Key Words: 6-Amino-3-aryl-2-methyl-4-(3H)-quinazolinones; Glycosyl derivatives; Synthesis; Spectral analysis

^{*}Corresponding author.

INTRODUCTION

It is well known that quinazolinones in general possess wide medical application as: anti-inflammatory^{1,2}, vasodilator and antihypertensive^{3,4}, anticonvulsant^{5,6}, antibacterial^{7,8}, anthelmintic⁹, CNS stimulance¹⁰, anticancer¹¹, and HIV activity^{12,13}. N-glycosides of substituted aniline have been reported to possess anticancer activity^{14,15}. In continuation of our work on the synthesis of biologically active compounds^{16–23}, we report in this article the synthesis of new N-glycosides derived from 6-amino-3-aryl-2-methyl-4(3H)-quinazolinones as shown in Scheme 1, and their screening for these derivatives as anti-HIV activity.

RESULTS AND DISCUSSION

Glycosidation was carried out by the methods usually employed for the synthesis of N-glycosylarylamines²⁴. 6-Amino-3-aryl-2-methyl-4-(3H)-quinazolinones^{25,26} (1a-c) readily react with monosaccharides, namely D-glucose (2a), D-galactose (2b), D-xylose (2c) or L-arabinose (2d) in boiling methanol in the presence of glacial acetic acid as a catalyst to yield the corresponding N-glucosides 3a-c, N-galactosides 4a-c, N-xylosides 5a,b or N-arabinosides 6a,b, respectively, Scheme 1. The structures of glycosides 3-6 were assessed by elemental analysis, IR and NMR (see experimental section). In solution the glycosides 3-6 existed in the form of a mixture of anomers as has often been observed in several N-glycosides of arylamines²⁷.

Attempts to isolate the individual anomers from these mixtures were unsuccessful. The IR (KBr) spectra of compounds 3-6 showed strong absorption bands in the 3360–3430 cm⁻¹ region due to the hydroxyl groups of the sugar residue and the NH group of the aglycon, in addition to the characteristic bands of quinazolinone nucleus²⁸ at 1620, 1570 and 1480 cm⁻¹. The configuration and confirmation of N-glycosides 3-6 were determined by ¹H NMR spectra (see experimental section). The N-glycosides 3a-c were a mixtures of β - and α -anoers (approximately in a ratio 5:1) in the pyranose form and the ${}^{4}C_{1}$ (D) conformation. The ${}^{1}H$ NMR spectra of compounds 3a-c in DMSO-d₆ were characterized by two triplets at δ 5.04-5.34 and δ 4.40-4.43. Upon deuterium exchange, the two triplets of the anomeric proton collapsed to two doublets and simultaneously the signal of the 1-NH disappeared. Coupling constants $(J_{1',2'})$ for the predominating anomers in compounds 3a-c (8.1-8.6 Hz) correspond to the diaxial orientation of H-1' and H-2' which indicates the β -configuration and ${}^{4}C_{1}$ (D) conformation. The small value of $J_{1',2'}$ in the minor anomer (4.2–4.6 Hz) is consistent with its α-configuration in the same conformation. This conclusion was confirmed by 13 C NMR spectra. The signals at δ 84.9 and δ 81.1 of compound 3a are attributed to the C-1' atom of the β -and α -anomers, respectively.

Acetylation of compounds **3a-c**, **4a-c**, **5a,b** and **6a,b** with acetic anhydride in pyridine at room temperature proceed normally and gave 3-aryl-2-methyl-[6-(per-O-acetyl-glycopyranosyl)amino]-4-(3H)-quinazolinone derivatives **7a-c**, **8a-c**, **9a,b** and **10a,b** which were identified on the basis of elemental analysis, IR, ¹H-NMR, ¹³C-NMR and mass spectroscopy. The IR spectra of compounds **7–10** exhibited a very strong band at 1749 cm⁻¹ assigned to the stretching vibration of the ester carbonyl group. The ¹H NMR spectra of compounds **7–9** indicated the β-configuration for these

Scheme 1.

compounds and the 4C_1 (D) conformation and the α -configuration for compound 10 and 4C_1 (L) conformation.

The spectrum of compound **7a** displays one doublet for the anomeric proton at δ 4.88 ($J_{1',2'}$ 9.0 Hz) while in the spectrum of compound **8a** this doublet appears at δ 4.87 ($J_{1',2'}$ 9.6 Hz) (see Experimental Section). The ¹H NMR (DMSO-d₆) spectra of compounds **10a,b** showed the α -configuration and ⁴C₁(L) conformation, based upon the coupling constant values for **10a** ($J_{1',2'} = J_{2',3'}$ 8.6 Hz, $J_{3',4'}$ 3.0 Hz) which indicate the axial positions for the $H_{1'}$, $H_{2'}$ and $H_{3'}$ and equatorial positions for the proton $H_{4'}$ (see Experimental Section).

This conclusion was confirmed by 13 C NMR spectra. The 13 C NMR spectrum of compound **7a** was characterized by a signal at δ 84.0 corresponding to C-1′ of the β -anomer. Four signals attributed to the four acetoxy carbonyl carbons at δ 169.6, 170.0, 170.8 and 171.3 and signals at δ 20.6, 20.7, 20.8 and 20.9 corresponding to the four methyl carbons of the acetoxy groups. The signals at δ 71.1, 72.5, 66.5, 72.9 and 61.9 were assigned to C-2′, C-3′, C-4′, C-5′ and C-6′ of the glucosyl residue, respectively. The quinazolinone signals at δ 151.3, 161.3, 121.6, 108.1, 143.2, 123.2, 128.0, 130.2 can be attributed to the C-2, C-4, C-4a, C-5, C-6, C-7 C-8 and C-8a, respectively. Signals for the 3-phenyl group lie at δ 138.0, 124.7, 129.2 and 128.0, corresponding to the respective a, b, c and d aromatic carbon atoms.

The structures of acetylated compounds 7–10 were confirmed by mass spectrometry (see Experimental Section). In the mass spectrum of compound 7b, the molecular ion was observed at m/z 595 (74%) and the loss of the sugar moiety produced m/z 308 (3%). Direct cleavage of the glycosidic bond produced m/z 265 (base+1) (12%) and 331 (sugar moiety (2%), such phenomena are common in reference mass spectra of N-glycosides²⁹.

Compounds **5b**, **7a**, **8c** and **8a** were tested as inhibitors of the L-1210 leukemia in mice and none of them showed significant anticancer activity. These compounds were but tested "*in vitro*" as inhibitors of the HIV virus, but none of these compounds showed anti-AIDS activity. These tests was carried out at the National Cancer Institute (NCI) according to the method reported in literature³⁰.

EXPERIMENTAL

All melting points are uncorrected. IR spectra were recorded with a UNICAM SP. 1200 spectrophotometer using pellet technique KBr discs. Microanalyses were performed in Faculty of Science, Cairo University, Cairo, Egypt. ¹H NMR and ¹³C NMR spectra were recorded with a Bruker AC spectrometer (400 MHz) in DMSO-d₆ and CDCl₃, shifts are expressed in δ values. The mass spectral data were obtained with micro mass spectrometer

model 7070F at of 70 ev and an inlet temperature of 90 °C. All analytical samples were tested by thin layer chromatography which was performed on EM silica gel 60 F_{254} sheets (0.2 mm). Compounds 1a-c were prepared as reported in the literature 25,26 .

General Procedure for the Synthesis of 3-Aryl-2-methyl-6- [(D-glucopyranosyl) amino]-4-(3H)-quinazolinone Derivatives (3a-c)

A mixture of compounds **1a-c** (0.01 mole) and D-glucose (**2a**, 0.01 mole) and glacial acetic acid (2.2 ml) in methanol (40 ml) was heated at reflux (TLC-monitored). Methanol was then evaporated under vacuum to one-third of its volume, kept at room temperature and the precipitate was then filtered off, dried and crystallized from methanol.

- Compound 3a: Yield, 65%, m.p. 128–30 °C, IR (KBr); 3360–3430 (*NH*, *OH*) and 1670 cm⁻¹ (CO of quinazolinone); ¹H NMR (DMSOd₆): δ 2.06 (s, 3*H*, 2-CH₃); 4.43 (t, 1*H*, β *H*-1', J_{1',2'} 8.5 Hz); 5.04 (t, 1*H*, α *H*-1', J_{1',2'} 4.2 Hz); 3.21–5.80 (m, 6*H*, *H*-2', *H*-3', *H*-4', *H*-5', *H*-6', *H*-6''); 6.80 (s, 1H, *NH* disappeared with D₂O); 7.20–7.55 (m, 8*H*, Ar-H); ¹³C NMR (DMSO-d₆) for aglycone: δ 150.7 (C-2); 159.8 (C-4); 121.5 (C-4a); 105.3 (C-5); 145.5 (C-6); 122.4 (C-7); 127.2 (C-8); 134.5 (C-8a); 138.8 (C-1 of Ph); 129.3 (2C, C-2,6 of Ph); 128.4 (2C, C-3,5 of Ph); 128.9 (C-4 of Ph); 21.4 (2-CH₃); for β-anomer: 84.9 (C-1'); 72.89 (C-2'); 77.22 (C-3'); 69.89 (C-4'); 77.50 (C-5'); 60.73 (C-6'); for α-anomer: 81.1 (C-1'); 70.9 (C-2'); 71.5 (C-3'); 70.1 (C-4'); 72.2 (C-5'); 60.6 (C-6'). Anal. Calcd for C₂₁H₂₃O₆N₃: C, 61.02; H, 5.61; N, 10.1. Found: C, 60.90; H, 5.47; N, 10.11.
- Compound 3b: Yield, 50%, m.p. 170–72°C, IR (KBr): 3348–3405 (*NH*, *OH*) and 1664 cm⁻¹ (CO of quinazolinone); ¹H NMR (DMSOd₆): δ 2.53 (s, 3H, 2-CH₃); 2.57 (s, 3*H*, *m*-CH₃); 4.42 (t, β *H*-1′, *J*_{1′,2′} 8.1 Hz); 5.32 (t, 1*H*, α *H*-1′, *J*_{1′,2′} 4.6 Hz); 3.15–5.13 (m, 6*H*, *H*-2′, *H*-3′, *H*-4′, *H*-5′, *H*-6′, *H*-6″); 6.72 (s, 1H, *NH* disappeared with D₂O); 7.16–7.38 (m, 7H, Ar-H); ¹³C NMR (DMSO-d₆): For aglycone: δ 149.3 (C-2); 161.7 (C-4); 121.0 (C-4a); 106.2 (C-5); 145.9 (C-6); 121.7 (C-7); 127.2 (C-8); 139.2 (C-8a); 138.2 (C-1 of Ph); 128.5 (C-2 of Ph); 139.5 (C-3 of Ph); 128.3 (C-4 of Ph); 127.1 (C-5 of Ph), 128.7 (C-6 of Ph); 23.4 (2-CH₃); 23.5 (*m*-CH₃), for β-anomer; 84.9 (C-1′); 73.0 (C-2′); 77.2 (C-3′); 70.0 (C-4′); 77.5 (C-5′); 60.7 (C-6′). For α-anomer: 80.8 (C-1′); 70.5 (C-2′); 71.8 (C-3′); 70.2 (C-4′); 72.2 (C-5′); 61.1 (C-6′). Anal. Calcd for C₂₂H₂₅O₆N₃: C, 61.86; H, 5.95; N, 9.84. Found: C, 61.63; H, 5.89; N, 9.73.
- **Compound 3c:** Yield 60% m.p. 105–07 °C. IR (KBr); 3270–3400 (*NH*, *OH*) and 1680 cm⁻¹ (CO of quinazolinone); ¹H NMR (DMSO-d₆): δ 2.09 (s 3*H*, 2-CH₃); 3.80 (s, 3*H*, *p*-OCH₃); 4.40 (t, β *H*-1', *J*_{1',2'}

8.6 Hz); 5.34 (t, 1H-1', αH -1', $J_{1',2'}$ 4.4 Hz); 3.05–5.42 (m, 6H-1', H-2', H-3', H-4', H-5', H-6', H-6''); 6.68 (s, 1H, NH disappeared with D₂O) 7.10–7.43 (m, 7H, Ar-H). Anal. Calcd for C₂₂H₂₄O₇N₃: C, 59.59; H, 5.64; N, 9.48. Found: C, 59.43; H, 5.52; N, 9.37.

3-Aryl-2-methyl-6-[(D-galactopyranosyl)amino]-4-(3H)-quinazolinone Derivatives (4a-c)

Compounds $\mathbf{4a-c}$ were prepared by the same method as compounds $\mathbf{3a-c}$ using (0.01 mole each) of compounds $\mathbf{1a-c}$ and D-galactose (2b).

- Compound 4a: Yield 70%; m.p. 180–82°C: IR (KBr): 3365–3420 (NH, OH) and 1667 cm⁻¹ (CO of quinazolinone); Anal. Calcd for C₂₁H₂₃O₆N₃: C, 61.02; H, 5.61; N, 10.17. Found: C, 60.82; H, 5.39; N, 10.09.
- Compound 4b: Yield, 65%; m.p. 169–70 °C: IR (KBr): 3340–3400 (NH, OH) and 1669 cm⁻¹ (CO of quinazolinone). Anal. Calcd for C₂₂H₂₅O₆N₃: C, 61.86; H, 5.95; N, 9.84. Found: C, 61.58; H, 5.68; N, 9.70.
- Compound 4c: Yield, 75%; m.p. 140–42°C: IR (KBr): 3370–3405 (NH, OH) and 1669 cm⁻¹ (CO of quinazolinone). Anal. Calcd for C₂₂H₂₅O₇N₃: C, 59.59; H, 5.64; N, 9.48. Found: C, 59.33; H, 5.42; N, 9.27.

3-Aryl-2-methyl-6-[(D-xylopyranosyl)amino]-4-(3H)-quinazolinone Derivatives (5a,b)

Compounds **5a,b** were obtained as for **3a-c** using 0.01 mole each of **1a,c** and D-xylose (**2c**).

- Compound 5a: Yield 55%; m.p. 138–39°C: IR (KBr): 3342–3390 (NH, OH) and 1660 cm⁻¹ (CO of quinazolinone). Anal. Calcd for C₂₀H₂₁O₅N₃: C, 62.66; H, 5.48; N, 10.79. Found: C, 62.38; H, 5.18; N, 10.28.
- Compound 5b: Yield, 53%; m.p. 95–97°C: IR (KBr): 3340–3381 (NH, OH) and 1664 cm⁻¹ (CO of quinazolinone). Anal. Calcd for C₂₁H₂₃O₆N₃: C, 61.02; H, 5.57; N, 10.17. Found: C, 60.75; H, 5.29; N, 10.02.

3-Aryl-2-methyl-6-[(L-arabinopyranosyl)amino]-4-(3H)-quinazolinone Derivatives (6a,b)

Compounds **6a,b** was obtained similarly from compounds **1a,c** (0.01 mole each) and **L**-arabinose (**2d**).

- Compound 6a: Yield 60%; m.p. 216–17°C: IR (KBr): 3340–3400 (NH, OH) and 1669 cm⁻¹ (CO of quinazolinone). Anal. Calcd for C₂₀H₂₁O₅N₃: C, 62.66; H, 5.48; N, 10.79. Found: C, 62.16; H, 5.10; N, 10.47.
- Compound 6b: Yield, 63%; m.p. 135–136°C: IR (KBr): 3330–3420 (NH, OH) and 1668 cm⁻¹ (CO of quinazolinone). Anal. Calcd for C₂₁H₂₃O₆N₃: C, 61.02; H, 5.57; N, 10.17. Found: C, 60.88; H, 5.11; N, 10.00.

General Procedure for the Synthesis of 3-aryl-2-methyl-6-[(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)amino]-4-(3H)-quinazolinones (7a-c)

To a solution of 0.003 mole of compounds **3a-c** in anhydrous pyridine (35 ml), redistill acetic anhydride (25 ml) was added. The reaction mixture was left at room temperature (TLC-monitoring). The solution was then poured on ice-water (600 ml) and the formed precipitate was filtered off, washed with water and dissolved in ethanol. The solvent was evaporated in vacuum and recrystallized from ethanol and water to give compounds **7a-c**.

- Compound 7a: Yield 70%; m.p. 145°C: IR (KBr): 3350 (NH); 1748 (CO acetoxy) and 1680 cm⁻¹ (CO of quinazolinone); ¹H NMR (CDCl₃): δ 2.04–2.07 (2s, 12H, 4 COCH₃); 2.25 (s, 3H, 2-CH₃); 4.88 (t, 1*H*, β *H*-1' $J_{1',2'}$ 9.0 Hz); 5.08 (t, 1*H*, *H*-2', $J_{2',3'}$ 9.2 Hz); 5.38 (t, $1H, H-3', J_{3',4'}$ 9.4 Hz); 5.14 (t, $1H, H-4', J_{4',5'}$ 10.2 Hz); 3.88 (m, 1H, H-5', $J_{5'.6'}$ 5.3 Hz); 4.17 (dd, 1H, H-6'); 4.28 (dd, 1H, H-6''); 5.10 (s, 1H, NH disappeared with D_2O , $J_{1',NH}$ 8.8 Hz); 7.11–7.55 (m, 8H, Ar-H); 13 C NMR (CDCl₃): for aglycone: δ 151.3 (C-2); 161.3 (C-4); 121.6 (C-4a); 108.1 (C-5); 143.2 (C-6); 123.2 (C-7); 128.0 (C-8); 130.2 (C-8a); 138.0 (C-1 of Ph); 130.0 (2C, C-2,6 of Ph); 128.0 (2C, C-3,5 of Ph); 129.2 (C-4 of Ph); 24.1 (2-CH₃); for sugar: 84.0 (β C-1'); 71.1 (C-2'); 72.5 (C-3'); 68.5 (C-4'); 72.9 (C-5'); 61.9 (C-6'); 20.6, 20.8 (4 $COCH_3$); 169.6, 170.0, 170.8, 171.3 (COCH₃). Mass spectrum: m/z604 (6, M+Na), 582 (100, M+1), 581 (34, M⁺), 250 (20, B⁺), 2.61 (10, B+1), 331 $(5, glucosyl moiety, S^+)$. Anal. Calcd for C₂₉H₃₁O₁₀N₃: C, 59.90, H, 5.33; N, 7.23. Found: C, 59.90; H, 5.07; N, 7.00.
- Compound 7b: Yield, 76%; m.p. 147 °C: IR (KBr): 3332 (*NH*); 1746 (CO acetoxy) and 1684 cm⁻¹ (CO of quinazolinone) ¹H NMR (CDCl₃) δ 2.04–2.08 (2s, 12*H*, 4 COCH₃); 2.21 (s, 3*H*, 2-CH₃); 2.41 (s, 3*H*, *m*-CH₃); 4.87 (t, β *H*-1′, $J_{1',2'}$ 9.6 Hz); 5.09 (t, 1*H*, *H*-2′, $J_{2',3'}$ 9.3 Hz); 5.36 (t, 1*H*, *H*-3′, $J_{3',4'}$ 9.5 Hz); 5.16 (t, 1*H*, *H*-4′, $J_{4',5'}$ 10.1 Hz); 3.86 (m, 1*H*, *H*-5′, $J_{5',6'}$ 6.1 Hz); 4.16 (dd, 1*H*, *H*-6′, $J_{5',6''}$ 2.0 Hz); 4.29 (dd, 1*H*, *H*-6″); 5.12 (s, 1*H*, *NH* disappeared with D₂O,

 $J_{1',NH}$ 8.9 Hz); 7.09–7.55 (m, 7*H*, Ar-H); ¹³C NMR (CDCl₃): for aglycone: δ 151.4 (C-2); 161.2 (C-4); 121.6 (C-4a); 108.2 (C-5); 143.1 (C-6); 123.1 (C-7); 128.0 (C-8); 130.0 (C-8a); 137.9 (C-1 of Ph), 129.7 (C-2 of Ph); 141.3 (C-3 of Ph); 128.9 (C-4 of Ph); 128.5 (C-5 of Ph); 123.1 (C-6 of Ph); 24.1(2-CH₃); 29.7 (*m*-CH₃); for sugar: 84.1 (β C-1'); 71.2 (C-2'); 72.6 (C-3'); 68.5 (C-4'); 72.9 (C-5'); 61.9 (C-6'); 20.4, 20.6, 20.8 (COCH₃); 169.6, 170.0, 171.3 (COCH₃); Mass spectrum: m/z 618 (6, M+Na), 596 (100, M+1), 595 (33, M⁺); 264 (11, B⁺), 265 (6, B+1), 293 (21, B+26), 331 (5, glucosyl moiety, S⁺). Anal. Calcd for C₃₀H₃₃O₁₀N₃: C, 60.50; H, 5.55; N, 7.06: Found: C, 60.20; H, 5.23; N, 6.74.

• Compound 7c: Yield, 80%; m.p. 180 °C: IR (KBr): 3309 (*NH*); 1752 CO acetoxy) and 1674 cm⁻¹ (CO of quinazolinone); ¹H NMR (CDCL₃); δ 2.04–2.07 (4s, 12*H*, 4 COCH₃); 2.20 (s, 3*H*, 2-CH₃); 3.91 (s, 3*H*, p-OCH₃); 4.88 (t, β *H*-1', *J*_{1',2'} 9.2 Hz); 5.10 (t, 1*H*, *H*-2'); 5.37 (t, 1*H*, *H*-3'); 5.17 (t, 1*H*, *H*-4'); 3.88 (m, 1*H*, *H*-5'); 4.16 (dd, 1*H*, *H*-6'); 4.30 (dd, 1*H*, *H*-6"), 5.11 (s, 1*H*, *NH* disappeared with D₂O); 7.08–7.56 (m, 7*H*, Ar-H); Mass spectrum: *m*/*z* 612 (41, M+1). Anal. Calcd for C₃₀H₃₃O₁₁N₃: C, 58.92; H, 5.40; N, 7.87. Found: C, 58.38; H; 5.13; N, 7.29.

3-Aryl-2-methyl-6-[(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)amino]-4 (3H)-quinazolinones (8a–c):

Compound 8a-c were prepared from compounds 4a-c in the same manner as compounds 7a-c.

Compound 8a: Yield, 80% m.p. 130 °C: IR (KBr): 3352 (NH), 1749 (CO acetoxy) and 1658 cm⁻¹ (CO of quinazolinone), ¹H NMR (CDCl₃): δ 2.05–2.10 (2s, 12*H*, 4COCH₃); 2.19 (s, 3*H*, 2-CH₃); 4.87 (t, 1*H*, β *H*-1', $J_{1',2'}$ 8.7 Hz); 5.72 (t, 1*H*, *H*-2', $J_{2',3'}$ 9.2 Hz); 5.20 (t, $1H, H-3', J_{3',4'}$ 3.5 Hz); 5.47 (t, $1H, H-4', J_{4',5'}$ 2.6 Hz); 4.08 (m, 1H, H-5', $J_{5',6'}$ 6.4 Hz); 4.15 (dd, 1H, H-6', $J_{5',6''}$ 6.4 Hz); 4.13 (dd, 1H, H-6'); 4.15 (dd, 1H); 4.15 (dd, 1H); 4.16 (dd, 1H); 4.17 (dd, 1H); 4.18 (dd, 1H); 4.19 (d 6''), 5.22 (s, 1*H*, *NH* disappeared with D₂O, $J_{1',NH}$ 8.8 Hz); 7.13–7.50 (m, 8*H*, Ar-H); 13 C NMR (CDCl₃): for aglycone: δ 151.2 (C-2); 162.1 (C-4); 121.6 (C-4a); 108.3 (C-5); 143.3 (C-6); 122.9 (C-7); 128.0 (C-8); 141.2 (C-8a); 138.0 (C-1 of Ph); 129.9 (2C, C-2,6 of Ph); 128.0 (2C, C-3.5 of Ph); 129.2 (C-4 of Ph);); 24.1 (2-CH₃); for sugar: 84.3 (β C-1'); 68.7 (C-2'); 71.0 (C-3'); 67.3 (C-4'); 71.4 (C-5'); 61.4 (C-6'); 20.6, 20.6; 20.9 (COCH₃); 169.9, 170.2, 170.5, 171.5 (COCH₃). Mass spectrum: m/z 582(100, M +1); 581 (70, M⁺), 251 (17, B+1), 331 (7, galactosyl moiety S⁺), 271 (1.2, 331-AcOH), 229 (1, 271-CH₂CO), 187 (2, 229 - Ac⁺), 127 (7, 187-AcOH). Anal. Calcd for

- C₂₉H₃₁O₁₀N₃: C, 59.82; H, 5.33; N; 7.23. Found: C, 59.28; H, 5.19; N, 6.80.
- Compound 8b: Yield, 86% m.p. 160 °C: IR (KBr): 3330 (NH), 1752 (CO acetoxy) and 1680 cm⁻¹ (CO of quinazolinone), Mass spectrum m/z 596 (27, M+1). Anal. Calcd for C₃₀H₃₃O₁₀N₃: C, 60.50; H, 5.55; N, 7.06. Found: C, 60.19; H, 5.19; N; 6.80.
- Compound 8c: Yield, 89% m.p. 145°C: IR (KBr): 3310 (NH), 1736 (CO acetoxy) and 1671 cm⁻¹ (CO of quinazolinone), Mass spectrum m/z 612 (27, M+1). Anal. Calcd for C₃₀H₃₃O₁₁N₃: C, 58.92; H, 5.40; N, 6.87. Found: C, 58.49; H, 5.05; N, 6.38.

3-Aryl-2-methyl-6-[(2,3,4-tri-O-acetyl-β-D-xylopyranosyl)amino]-4 (3H)-quinazolinones (9a-c)

Compounds 9a-c were prepared from 5a,b in the same manner as for 7a-c.

- **Compound 9a:** Yield, 70% m.p. 140 °C: IR (KBr): 3330 (NH), 1752 (CO acetoxy) and 1673 cm⁻¹ (CO of quinazolinone), ¹H NMR (CDCl₃): δ 2.04–2.06 (3s, 9H, 3COCH₃); 2.19 (, 3H, 2-CH₃); 4.82 (t, 1*H*, β *H*-1', $J_{1',2'}$ 8.8 Hz); 5.07 (t, 1*H*, *H*-2', $J_{2',3'}$ 9.1 Hz), 5.35 (t, 1*H*, *H*-3', $J_{3',4'}$ 9.5 Hz); 5.09 (q, 1*H*, *H*-4', $J_{4',5a}$ 9.6 Hz); 4.09 (t, 1*H*, *H*-5a, $J_{4',5e}$ 5.7 Hz); 3.47 (t, 1*H*, *H*-5e, $J_{5a,5e}$ 11.6 Hz); 5.00 (s, 1*H*, *NH* disappeared with D_2O , $J_{1',NH}$ 8.1 Hz), 7.11–7.55 (m, 8H, Ar-H); 13 C-NMR (CDCl₃): for aglycone: δ 151.1 (C-2); 162.3 (C-4); 122.8 (C-4a); 108.1 (C-5); 143.4 (C-6); 130.0 (C-7); 128.0 (C-8); 137.97 (C-8); 141.2 (C-8a); 137.8 (C-1 of Ph); 129.7 (2C, C-2,6 of Ph); 128.5 (2C, C-3,5 of Ph); 128.8 (C-4 of Ph);); 24.1(2-CH₃); for sugar: 84.3 (β C-1'); 69.1 (C-2'); 68.2 (C-3'); 70.7(C-4'); 64.6 (C-5'); 20.8, 20.7; 20.7 $(CO\underline{CH_3})$; 169.2, 170.0, 171.2, (3COCH₃). Mass spectrum: m/z 509 (100, M+1); 508 (58, M⁺), 251 (7, B+1), 279 (32, B+29), 293 (8, B+43), 259 (3, xylosyl moiety, S^+). Anal. Calcd for $C_{26}H_{27}O_8N_3$: C, 61.95; H, 5.54; N, 8.25. Found: C, 61.49; H, 5.19; N, 8.09.
- Compound 9b: Yield, 74% m.p. $165 \,^{\circ}$ C: IR (KBr): 3338 (*NH*), 1748 (CO acetoxy) and $1679 \,^{\circ}$ (CO of quinazolinone), 1 H NMR (CDCl₃): δ 2.04–2.05 (3s, 9*H*, 3COCH₃); 2.21 (s, 3*H*, 2-CH₃); 4.81 (t, 1*H*, β *H*-1′, $J_{1',2'}$ 8.8 Hz); 5.03, (q, 1*H*, *H*-2′, $J_{2',3'}$ 9.2 Hz); 5.35 (t, 1*H*, *H*-3′, $J_{3',4'}$ 9.5 Hz); 5.06 (q, 1*H*, *H*-4′, $J_{4',5a}$ 9.8 Hz); 4.08 (t, 1*H*, *H*-5′a, $J_{4',5e}$ 5.6 Hz); 3.46 (t, 1*H*, *H*-5′e); 5.05 (s, 1*H*, *NH* disappeared with D₂O, $J_{1',NH}$ 8.4 Hz), 7.03–7.57 (m-7 *H*, Ar-H). Mass spectrum: m/z 540 (100, M+1); 539 (65, M⁺), 281 (20, B+1); 309 (42, B+29), 323 (5, B+ CH₃, CO), 259 (5,

xylosyl moiety, S⁺), 199 (7, 259-AcOH) 139 (4, 199-AcOH). Anal. Calcd for $C_{27}H_{29}O_8N_3$: C, 61.42; H, 5.43; N, 8.03. Found: C, 61.28; H, 5.19; N, 7.80.

3-Aryl-2-methyl-6-[(2,3,4-tri-O-acetyl-α-L-arabinopyranosyl)amino]-4 (3H)-quinazolinones (10a,b):

A mixture of compounds **6a,b** (0.003 mole) in anhydrous pyridine (32 ml) and acetic anhydride (22 ml) was treated as described for the preparation of compounds **7a,b**.

- Compound 10a: Yield 80%; m.p. 144°C: IR (KBr): 3330 (*NH*); 1752 (CO acetoxy) and 1683 cm⁻¹ (CO of quinazolinone); ¹H NMR (CDCl₃) δ 2.04–2.11 (3s, 9*H*, 3COCH₃); 2.19 (s, 3*H*, 2-CH₃); 4.81 (t, 1*H*, α *H*-1′, *J*_{1′,2′} 8.6 Hz); 5.19 (q, 1*H*, *H*-2′, *J*_{2′,3′} 8.6 Hz); 5.38 (t, 1*H*, *H*-3′, *J*_{3′,4′} 3.0 Hz); 5.28 (q, 1*H*, *H*-4′); 4.01 (t, 1*H*, *H*-5′e); 3.79 (t, 1*H*, *H*-5′a); 5.13 (s, 1*H*, *NH* disappeared with D₂O, *J*_{1′,NH} 7.5 Hz); 7.10–7.55 (m, 8*H*, Ar-H); ¹³C NMR (CDCl₃): for aglycone: δ 151.1 (C-2); 162.2 (C-4); 121.6 (C-4a); 108.1 (C-5); 143.37 (C-6); 123.02 (C-7); 129.00 (C-8); 141.16 (C-8a); 137.9 (C-1 of Ph); 129.9 (2C, C-2,6 of Ph); 128.0 (2C, C-3,5 of Ph); 129.2 (C-4 of Ph);); 29.7 (2-CH₃); for sugar: 84.5 (α C-1′); 69.0 (C-2′); 68.3 (C-3′); 70.7 (C-4′); 64.7 (C-5′); 20.9, 20.9, 20.7 (COCH₃); 169.9, 170.3, 171.5, (3COCH₃). Mass spectrum: *m*/*z* 509 (100, M+1). Anal. Calcd for C₂₆H₂₇O₈N₃: C, 61.30; H, 5.30; N, 8.25. Found: C, 61.09; H, 5.13; N, 8.18.
- Compound 10b: Yield 83%; m.p. 200 °C: IR (KBr): 3330 (*NH*); 1751 (CO acetoxy) and 1680 cm⁻¹ (CO of quinazolinone); ¹H NMR (CDCl₃): δ 2.04–2.10 (3s, 9*H*, 3COCH₃); 2.21 (s, 3*H*, 2-CH₃); 4.83 (t, 1*H*, a *H*-1', *J*_{1',2} 8.4 Hz); 5.19 (d, 1*H*, *H*-2', *J*_{2',3'} 8.4 Hz); 5.38 (d, 1*H*, *H*-3', *J*_{3',4'} 3.0 Hz); 5.27 (t, 1*H*, *H*-4'); 4.00 (d, 1*H*, *H*-5'a); 3.79 (d, 1*H*, *H*-5'e); 5.14 (s, 1*H*, *NH* disappeared with D₂O, *J*_{1',NH} 7.5 Hz); 7.03–7.55 (m, 7H, Ar-H). Mass spectrum: *m*/*z* 540 (100, M +1), 539 (58, M⁺); 281 (25, B+1), 309 (54, B+29), 223 (7, B+CH₃CO), 25(13, arabinosyl moiety, S⁺). Anal. Calcd for C₂₇H₂₉O₈N₃: C, 61.95; H, 5.54; N, 8.25. Found: C, 61.47; H, 5.11; N, 8.09.

ACKNOWLEDGMENTS

The authors are greatly indebted to Dr. John P. Bader and Dr. V. L. Narayanan, AIDS Department and Drug synthesis, Chemistry Branch of Health and Human Services, National Institute of Health for their valuable measurements of the anti-HIV activities of our samples.

REFERENCES

- 1. Plescia, S.; Bajard, M.L.; Raffa, D.; Daidane, C.; Matera, M.; Carusa, A.; Amico, R.N. Eur. J. Med. Chem. **1986**, *21*, 291.
- Mikhalev, A.I.; Konshim, M.E.; Yanborisova, O.A.; Zaks, A.S.; Yushkov, V.V. Khim-Farm. Zh 1991, 25, 37.
- 3. Buzas, A.; Moczar, M.; Pierre, R. Fr. Demand 2 **1971**, *068*, 442: [Chem. Abst. **1972**, *76*, 144846].
- 4. Ram, V.J.; Stimal, R.C.; Kushwaha, D.S.; Mishra, L. J. Prakt. Chem. **1990**, *332*, 629.
- 5. Johne, S. Drug Res. 1982, 26, 259.
- 6. Mirsa, V.S.; Gupta, P.N.; Pandey, R.N.; Nath, C.; Gupta, G.P. Pharmazie **1980**, *35*, 400.
- 7. Desai, K.R.; Mistry, B. J. Inst. Chem. (India) 1992, 64, 155.
- 8. El-Khamry, A.A.; El-Nagdy, S.; Habashy, M.M.; El-Bassiouny, F.A. Pharmazie 1989, 44, 312.
- 9. Husain, M.I.; Misra, S.N.; Yadav, S.R. J. Ind. Chem. Soc. 1980, 57, 924.
- 10. Lakhan, R.J.; Singh, R.I. Indian. J. Pharm. Sci. 1990, 52, 52.
- 11. Barker, A.J. Eur. Patent 1995, 635, 498.
- 12. Wolk, D.R.; Vesella, A.; Schweikart, F.; Peter, M.G. Helv. Chem. Acta **1992**, 75, 323.
- 13. Hirsh, J.; Petrakova, E.; Fealher, M.S.; Batnes, C.I. Carbohydr. Res. **1995**, 267, 17.
- 14. Tominage, T. Proceedings of Thirteenth International Cancer Congress, Seattle, Washington, USA, September 8, *15*, 1982; 1144, p. 202.
- Wang, L.; Maniglia, C.A.; Mella, S.L.; Sartorelli, A.C. J. Med. Chem. 1983, 26, 629.
- 16. Abdel-Megeed, M.F.; Saleh, M.A. Sulfur Letters 1987, 6, 115.
- 17. Salekh, M.A.; Krasavina, L.S.; Vigodorchik, M.M.; Turchin, K.F.; Kuleshovn, E.F.; Suvorov, M. Zh. Org. Khim. **1989**, *25* (12), 2613: [Chem. Abst. **1990**, *113*, 115694].
- 18. Saleh, M.A. Rev. Rom. Chem. **1994**, *39* (6), 650: [Chem. Abst. **1995**, *122*, 56329].
- 19. Abdo, M.A.; Abdel-Megeed, M.F.; Saleh, M.A.; El-Hiti, G.A. Polish. J. Chem. **1995**, *69*, 583.
- 20. Abdel-Megeed, M.F.; Saleh, M.A.; Abdo, M.A.; El-Hiti, G.A. Collect. Czech. Chem. Commun. **1995**, *60*, 1016.
- 21. Saleh, M.A.; Abdo, M.A.; Abdel Megeed, M.F.; El-Hiti, G.A. Indian J. Chem. **1996**, *28*, 5–7.
- 22. Abdel-Megeed, M.F.; Saleh, M.A.; Aly, Y.L.; Abdo, I.M. Nucleotides and Nucleosides **1995**, *14*, 1985.
- 23. Abdel-Megeed, M.F.; Aly, Y.L.; Saleh, M.A.; Abdo, I.M.; El-Hiti, G.A.; Smith, K. Sulfur Letters **1995**, *19*, 129.
- 24. Wany, L.; Maniglia, C.A.; Mella, S.L.; Sartoreli, A.C. J. Med. Chem. **1983**, *26*, 629.
- 25. Yamada, Y. Chem. Pharm. Bull. 1983, 34 (4), 1158.

 Jiang, J.B.; Hesson, D.P.; Dusak, B.A.; Dexter, D.I.; Kang, G.J.; Hamel, E. J. Med. Chem. 1990, 33 (6), 1721.

- 27. Ellis, G.P.; Honeyman, J. Adv. Carbohyd. Chem. 1995, 10, 95.
- 28. Naggar, G.M.; El-Shwrief, H.A.H.; Abdel-Hamid, K. Pharmazie 1983, 38, 821.
- 29. Dolhun, J.; Wiebers, J.L. Org. Mass. Spectrometry 1970, 3, 669.
- 30. Weislow, O.W.; Kiser, R.; Fine, D.; Bader, J.; Shoemaker, R.H.; Boyd, M.R. J. Nat. Cancer Inst. **1989**, *81*, 577.

Received July 31, 2000 Accepted July 16, 2001